Treatment of bone loss in osteopenic patients with Crohn's disease: A double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Gut

Volumn 63, Issue 9, 2014, Pages 1424-1430

  Van Bodegraven, Ad A ^a   Bravenboer, Nathalie ^a   Witte, Birgit I ^a   Dijkstra, Gerard ^b   Van Der Woude, C Janneke ^c   Stokkers, Pieter C M ^d,e   Russel, Maurice G ^f   Oldenburg, Bas ^g   Pierik, Marieke ^h   Roos, Jan C ^a   Van Hogezand, Ruud A ⁱ   Dik, Vincent K ^a,g   Oostlander, Angela E ^a   Netelenbos, J Coen ^a   Van De Langerijt, Lex ^j   Hommes, Daniel W ^e,i,k   Lips, Paul ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Dept of Medical Research   (Netherlands)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPENIA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

BONE DISEASE; BONE MINERAL DENSITY; CLINICAL TRIALS; CROHN'S DISEASE; OSTEOPOROSIS;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIUM; CROHN DISEASE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D;

EID: 84905587802     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305523     Document Type: Article

References (34)

1. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
2. Jahnsen J, Falch JA, Mowinckel P, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004;39:145-53. (Pubitemid 38253626)
3. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002;51:654-8. (Pubitemid 35216851)
4. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012;11:234-50.
5. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:857-64. (Pubitemid 36904453)
6. Schoon EJ, van Nunen AB, Wouters RS, et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000;232:43-7. (Pubitemid 32142736)
7. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81. (Pubitemid 30305842)
8. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003;125:1591-7. (Pubitemid 37500422)
9. Siffledeen JS, Siminoski K, Jen H, et al. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007;5:721-8. (Pubitemid 46830056)
10. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011;300:G191-201.
11. van Hogezand RA, Banffer D, Zwinderman AH, et al. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int 2006;17:535-42.
12. Turk N, Cukovic-Cavka S, Korsic M, et al. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009;21:159-66.
13. Oostlander AE, Bravenboer N, Sohl E, et al. Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease. Gastroenterology 2010;140:116-23.
14. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36. (Pubitemid 34615775)
15. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
16. Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009;63:19-26.
17. von Tirpitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003;17:807-16. (Pubitemid 36418878)
18. Stokkers PC, Deley M, Van der Spek M, et al. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand J Gastroenterol 2006;41:200-4. (Pubitemid 43247203)
19. Abitbol V, Briot K, Roux C, et al. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:1184-9. (Pubitemid 47496232)
20. Bartram SA, Peaston RT, Rawlings DJ, et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003;18:1121-7. (Pubitemid 38021598)
21. Sbrocchi AM, Forget S, Laforte D, et al. Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int 2010;52:754-61.
22. Klaus J, Reinshagen M, Herdt K, et al. Intravenous ibandronate or sodium-fluoride-a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. J Gastrointestin Liver Dis 2011;20:141-8.
23. Klaus J, Haenle MM, Schroter C, et al. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. Am J Gastroenterol 2011;106:786-93.
24. Haderslev KV, Tjellesen L, Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.
25. Palomba S, Orio F Jr, Manguso F, et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005;16:1141-9. (Pubitemid 41225101)
26. Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006;101:119-23. (Pubitemid 43381718)
27. Tsujikawa T, Andoh A, Inatomi O, et al. Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease. Intern Med 2009;48:933-7.
28. Soo I, Siffledeen J, Siminoski K, et al. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. J Crohns Colitis 2012;6:777-86.
29. Bone HG, Hosking D, Devogelaer JP, et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189-99. (Pubitemid 38339363)
30. Bakker SF, Dik VK, Witte BI, et al. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation. J Crohns Colitis 2013;7:377-84.
31. Veerappan SG, O'Morain CA, Daly JS, et al. Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:1261-72.
32. Oostlander AE, Bravenboer N, van Essen HW, et al. Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. J Cell Biochem 2012;113:2424-31.
33. Oostlander AE, Everts V, Schoenmaker T, et al. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss. J Cell Biochem 2012;113:260-8.
34. Link TM. Osteoporosis imaging: state of the art and advanced imaging. Radiology 2012;263:3-17.